Concepedia

M. Elmer

ME

9

Publications

1.6K

Citations

9

H-Index

2003

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Erasmus MC Cancer Institute

Copenhagen University Hospital

Erasmus MC

Herlev Hospital

M. Elmer is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

2003–2020

9

Publications

9

The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

Paul J. Hesketh, Steven M. Grunberg, Richard J. Gralla et al. · Journal of Clinical Oncology · 2003 · 770 citations

Establishing the dose of the oral NK<sub>1</sub> antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting

Sant P. Chawla, Steven M. Grunberg, Richard J. Gralla et al. · Cancer · 2003 · 216 citations · Full text

Addition of the Oral NK<sub>1</sub> Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy

Ronald de Wit, Jørn Herrstedt, Bernardo L. Rapoport et al. · Journal of Clinical Oncology · 2003 · 148 citations

The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.

Ronald de Wit, Jørn Herrstedt, Bernardo L. Rapoport et al. · PubMed · 2004 · 146 citations

Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index?Emesis (FLIE) with 5-day recall

Beilei Cai, M. Elmer, Celeste Lindley et al. · Supportive Care in Cancer · 2003 · 140 citations

, , +6

Rows per page

1–5 of 9